EUVIMEDEUVIMED entdecken
Crossref

A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation

Jin-Sil Park, SeungCheon Yang, Doona Song, Sung-Min Kim, JeongWon Choi, Hye Yeon Kang, Ha Yeon Jeong, Gyoonhee Han, Do Sik Min, Mi-La Cho, Sung-Hwan Park

Immunology Letters · 2023

DOI: 10.1016/j.imlet.2023.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology Letters, 2023. Verfasst von Jin-Sil Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul 06591, Republic of Korea; Lab…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Phospholipase D, Arthritis, Experimental. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Ministry of Health and Welfare, Korea Health Industry Development Institute, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phospholipase D1 (PLD1), which catalyzes the hydrolysis of phosphatidylcholine to phosphatidic acid and choline, plays multiple roles in inflammation. We investigated the therapeutic effects of the newly developed PLD1 inhibitors A2998, A3000, and A3773 in vitro and in vivo rheumatoid arthritis (RA) model. A3373 reduced the levels of LPS-induced TNF-α, IL-6, and IgG in murine splenocytes in vitro. A3373 also decreased the levels of IFN-γ and IL-17 and the frequencies of Th1, Th17 cells and germinal-center B cells, in splenocytes in vitro. A3373 ameliorated the severity of collagen-induced arthritis (CIA) and suppressed infiltration of inflammatory cells into the joint tissues of mice with CIA compared with vehicle-treated mice. Moreover, A3373 prevented systemic bone demineralization in mice with CIA and suppressed osteoclast differentiation and the mRNA levels of osteoclastogenesis markers in vitro. These results suggest that A3373 has therapeutic potential for RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPhospholipase DArthritis, ExperimentalMiceAnimalsOsteoclastsCell DifferentiationCytokinesTh17 Cells

Stichwörter der Autor:innen

Collagen-induced arthritisInflammatory cytokinesOsteoclastogenesisPhospholipase D1Rheumatoid arthritis

Substanzen

phospholipase D1Phospholipase DCytokines

Autor:innen und Institutionen

  • The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul 06591, Republic of Korea; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medic…
  • Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon 21983, Republic of Korea; Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republi…
  • Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon 21983, Republic of Korea; Department of Pharmacy, Yonsei University, Incheon 21983, Republic of Korea.
  • Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon 21983, Republic of Korea; Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Republic of…

Förderung

  • Ministry of Health and Welfare
  • Korea Health Industry Development Institute
  • Ministry of Education
  • National Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning

Zitieren

APA

Park, J. S., Yang, S., Song, D., Kim, S. M., Choi, J., Kang, H. Y., Jeong, H. Y., Han, G., Min, D. S., Cho, M. L., & Park, S. H. (2023). A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation. Immunology Letters. https://doi.org/10.1016/j.imlet.2023.09.007

Vancouver

Park JS, Yang S, Song D, Kim SM, Choi J, Kang HY, et al. A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation. Immunology Letters. 2023. doi:10.1016/j.imlet.2023.09.007

BibTeX
@article{Park2023,
  author = {Park, Jin-Sil and Yang, SeungCheon and Song, Doona and Kim, Sung-Min and Choi, JeongWon and Kang, Hye Yeon and Jeong, Ha Yeon and Han, Gyoonhee and Min, Do Sik and Cho, Mi-La and Park, Sung-Hwan},
  title = {A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation},
  journal = {Immunology Letters},
  year = {2023},
  doi = {10.1016/j.imlet.2023.09.007}
}
Kostenlos starten →